Biosimilars stocks
바이오시밀러
What are Biosimilars stocks in Korea?
The Biosimilars theme on jonbur groups 13 Korean stocks listed on KOSPI and KOSDAQ, worth ₩143T in total. On Oct 30, 2026 the group moved up 4.19% (weighted by market value); the largest members are Samsung Biologics, Celltrion, Alteogen.
Key facts
- Stocks
- 13
- Total market value
- ₩143T
- Day's move
- +4.19%
- As of
- Oct 30, 2026
- Largest members
- Samsung Biologics, Celltrion, Alteogen
Earnings tracker · 3Q 2026
Reporting season · reports due by Nov 14
Combined, for the companies that have reported, vs the same quarter a year ago
| Company | Reported | Revenue | vs a year ago | Operating profit | vs a year ago | vs last quarter | Op. margin |
|---|---|---|---|---|---|---|---|
| Celltrion | Oct 12Preliminary | ₩1.5T | +45.8% | ₩510B | +69.2% | +12.9% | 34.0%29.3% |
| Samsung Epis Holdings | Oct 28Preliminary | ₩442B | +0.3% | ₩133B | +2.8% | +125.8% | 30.0%29.3% |
| CKD Bio | Oct 30Preliminary | ₩29B | −14.0% | −₩6B | Bigger loss | Bigger loss | −20.4%−4.3% |
| Samsung Biologics | Expected around Oct 28 | ||||||
| ISU Abxis | Expected around Nov 6 | ||||||
| Aprogen Biologics | Expected around Nov 13 | ||||||
| Alteogen | Expected around Nov 14 | ||||||
| SAM Chun Dang Pharm | Expected around Nov 14 | ||||||
| Celltrion Pharm | Expected around Nov 14 | ||||||
| Komipharm International | Expected around Nov 14 | ||||||
| Prestige Biologics | Expected around Nov 14 | ||||||
| Prestige BioPharma | Expected around Nov 28 | ||||||
| IMBiologics | Not yet | ||||||
Single-quarter figures. Preliminary figures are the company's own early numbers and are replaced by the quarterly report when it's filed. Expected dates are around when each company reported a year ago.
Technical breadth
After the close on Oct 30, 2026- Above 20-day average
- 15.4%
- Above 60-day average
- 23.1%
- RSI above 70
- 0%
- RSI below 30
- 23.1%
- 52-week highs
- 0
- 52-week lows
- 2
Index gauge · Short term
Bearish
0 bullish, 2 neutral, 7 bearish
Index gauge · Medium term
Bearish
0 bullish, 1 neutral, 7 bearish
Technical read
The Biosimilars theme covers 13 Korean member stocks, and only 15.4% of them trade above their 20-day average while 23.1% sit above their 60-day average. No member is at a 52-week high, two are at 52-week lows, and the lowest RSI reading is 23.1 with no overbought readings. The equal-weighted member index screens bearish on both short and medium horizons, with seven of its signals bearish and none bullish, an RSI of 33.1, and the index trading below its cloud.
Written by AI from the indicator values above. Not advice.
Share of members, from each member's own indicators; the gauge reads an equal-weighted index of the members. Technical indicators describe past price and volume patterns. They are not predictions or recommendations.
Credit & macro
- MaturitiesOct 23, 202685ISU Abxis: ₩50bn of bonds due in the next 6 months vs ₩23bn cash₩50bn due within 12 months, from the bond filings so far; cash and cash equivalents as of 2026 H1.ISU Abxis
ETFs for this theme
All ETFs →AUM · Flow 1w
Biosimilars
−8.68%바이오시밀러
Biosimilars are copies of biologic drugs, which are complex medicines made from living cells, that are shown to be highly similar to an already-approved reference product in quality, safety, and efficacy. Korean investors group the theme together because several domestic companies, including Samsung Biologics, Celltrion, and Hanmi-linked developers, have built large manufacturing or development capabilities in this area. Because the sector sits at the intersection of pharmaceuticals, contract manufacturing, and patent-expiry timelines, the theme is often discussed as a single category even though individual companies differ in business models.
13 companies · 3 up · 0 flat · 10 down
- Traded value
- ₩345B
- Value vs 20-day average
- 1.03×
- Top gainer
- SAM Chun Dang Pharm +9.99%
- Largest company
- Samsung Biologics ₩69T
Companies in this theme
| Company | Price | Monthly | Traded value | Market cap | NPS |
|---|
Source: KRX statistical information